| 2025-11-14 |
详情>>
股本变动：
变动后总股本4585.72万股
|
| 2025-11-14 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-0.18美元,归母净利润-842.3万美元,同比去年增长-17.26%
|
| 2025-08-08 |
详情>>
业绩披露：
2025年中报每股收益-0.12美元,归母净利润-522.3万美元,同比去年增长-25.49%
|
| 2025-07-16 |
详情>>
内部人交易：
Burshtein Gregory等共交易3笔
|
| 2025-06-05 |
股东大会：
将于2025-07-16召开股东大会
会议内容 ▼▲
- 1.To elect Ms. Haya Taitel to serve as a Class II director of the Company until the Company’s annual general meeting of shareholders to be held in 2028;
2.To ratify and approve the compensation terms to Ms. Miranda Toledano, our Chief Executive Officer and a Director;
3.To ratify and approve the compensation terms, as described in the accompanying proxy statement, to Dr. Gregory Burshtein, our Chief of Research and Development;
4.To ratify and approve the compensation terms, as described in the accompanying proxy statement, to Ms. Dana Yaacov-Garbeli, our Chief Financial Officer;
5.To ratify and approve the amended and restated compensation policy for the directors and officers of the Company;
6.To consider and vote on the advisory resolution regarding the compensation of our named executive officers;
7.To ratify and approve the appointment of Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Limited, or PwC, an independent registered public accounting firm, as the Company’s independent auditors for the fiscal year ending December 31, 2025, and authorize the Board, or the Audit Committee, if authorized by the Board, to determine the compensation of the auditors in accordance with the volume and nature of their services.
8.To consider any other business as may properly come before the Annual Meeting and any adjournment or postponement of the Annual Meeting.
|
| 2025-05-09 |
详情>>
业绩披露：
2025年一季报每股收益-0.06美元,归母净利润-256.7万美元,同比去年增长-27.27%
|
| 2025-03-28 |
详情>>
业绩披露：
2024年年报每股收益-0.25美元,归母净利润-954.1万美元,同比去年增长-7.33%
|
| 2024-11-08 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.19美元,归母净利润-718.3万美元,同比去年增长-4.19%
|
| 2024-08-09 |
详情>>
业绩披露：
2024年中报每股收益-0.11美元,归母净利润-416.2万美元,同比去年增长7.82%
|
| 2024-06-20 |
股东大会：
将于2024-07-31召开股东大会
会议内容 ▼▲
- 1.To elect each of the following nominees to serve as Class I directors of the Company until the Company’s annual general meeting of shareholders to be held in 2027:(a)Ms. Miranda Toledano;(b)Mr. Yonatan Malca;
2.To ratify and approve a one-time grant of compensation, as described in the accompanying proxy statement, to Ms. Miranda Toledano, our Chief Executive Officer and a Director;
3.To ratify and approve the revised compensation terms for our non-executive directors;
4.To ratify and approve an amendment to the Company's 2018 Equity Incentive Plan (the “2018 Plan”), including an increase of the number of shares issuable thereunder by a one-time amount of 1,788,515 shares;
5.To ratify and approve the amended and restated compensation policy for the directors and officers of the Company;
6.To consider and vote on the advisory resolution regarding the compensation of our named executive officers;
7.To consider and vote on the advisory resolution on the frequency of the advisory resolution regarding the compensation of our named executive officers;
8.To ratify and approve the appointment of Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Limited, or PwC, an independent registered public accounting firm, as the Company’s independent auditors for the fiscal year ending December 31, 2024, and authorize the Company’s board of directors (the “Board”), or the Audit Committee, if authorized by the Board, to determine the compensation of the auditors in accordance with the volume and nature of their services;
9.To consider any other business as may properly come before the Annual Meeting and any adjournment or postponement of the Annual Meeting.
|
| 2024-05-10 |
详情>>
业绩披露：
2024年一季报每股收益-0.05美元,归母净利润-201.7万美元,同比去年增长7.90%
|
| 2024-03-08 |
详情>>
业绩披露：
2023年年报每股收益-0.31美元,归母净利润-888.9万美元,同比去年增长31.99%
|
| 2023-11-14 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.24美元,归母净利润-689.4万美元,同比去年增长31.31%
|
| 2023-08-15 |
股东大会：
将于2023-09-13召开股东大会
会议内容 ▼▲
- 1.To elect each of the following nominees to serve as Class III directors of the Company until the Company’s annual general meeting of Shareholders to be held in 2026:(a)Mr. Gerald Lieberman;(b)Mr. Gerald Ostrov;(c)Mr. Sean Ellis;
2.To ratify and approve the revised compensation terms, as described in the accompanying proxy statement, for Ms. Miranda Toledano, our Chief Executive Officer and a Director;
3.To ratify and approve a one-time grant of compensation to Ms. Haya Taitel, a Director;
4.To authorize the Board of Directors of the Company (the “Board”) to, if the Board deems it necessary in order to comply with the continued listing requirements of the Nasdaq Stock Market (“Nasdaq”), approve an amendment to the Articles of Association of the Company to effect a reverse share split (the “Reverse Share Split”) with respect to the Ordinary Shares of the Company, par value ILS 0.0000769 per share (the “Ordinary Shares”), at any time prior to September 13, 2024, at a ratio within a range between five (5) pre-reverse-split shares for one (1) post-reverse-split share and eleven (11) pre-reverse-split shares for one (1) post-reverse-split share (the “Range”), with the ratio at which the Reverse Share Split would be effected (the “Effective Ratio”) to be a ratio within the Range to be determined at the discretion of the Board and included in a public announcement by the Company before the effectiveness of the Reverse Share Split.
5.To ratify and approve the appointment of Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Limited, or PwC, an independent registered public accounting firm, as the Company’s independent auditors for the fiscal year ending December 31, 2023, and authorize the Company’s board of directors (the “Board”) (or the Audit Committee, if authorized by the Board) to determine the compensation of the auditors in accordance with the volume and nature of their services;
6.To consider any other business as may properly come before the Annual Meeting and any adjournment or postponement of the Annual Meeting.
|
| 2023-08-11 |
详情>>
业绩披露：
2023年中报每股收益-0.16美元,归母净利润-451.5万美元,同比去年增长35.21%
|
| 2022-07-29 |
股东大会：
将于2022-09-07召开股东大会
会议内容 ▼▲
- 1.To elect Yonatan Malca as a Class II director, as described in the accompanying proxy statement, to serve for a three-year term or until his successor is elected;
2.To ratify and approve certain compensation items, as described in the accompanying proxy statement, relating to Dr. Phillip Schwartz, our former President of Research and Development;
3.To ratify and approve a one-time grant of compensation, as described in the accompanying proxy statement, to Dr. Arthur Santora, our Chief Medical Officer;
4.To ratify and approve the compensation terms, as described in the accompanying proxy statement, to Miranda J. Toledano, our Chief Executive Officer;
5.To ratify and approve certain compensation items, as described in the accompanying proxy statement, relating to Dana Yaacov-Garbeli, our Chief Financial Officer;
6.To ratify and approve the amended terms of compensation of the Company’s Chairman of the Board of Directors;
7.To ratify and approve an amendment to the Company's 2018 Equity Incentive Plan (the “2018 Plan”) to increase the number of shares issuable thereunder by a one-time amount of 576,188 shares;
8.To ratify and approve the appointment of Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Limited, or PwC, an independent registered public accounting firm, as the Company’s independent auditors for the fiscal year ending December 31, 2022, and authorize the Company’s board of directors (the “Board”) (or the Audit Committee, if authorized by the Board) to determine the compensation of the auditors in accordance with the volume and nature of their services;
9.To consider any other business as may properly come before the Annual Meeting and any adjournment or postponement of the Annual Meeting.
|
| 2022-05-12 |
财报披露：
美东时间 2022-05-12 盘前发布财报
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-08-23 |
股东大会：
将于2021-10-04召开股东大会
会议内容 ▼▲
- 1.To ratify and approve the appointment of Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Limited, or PwC, an independent registered public accounting firm, as the Company’s independent auditors for the fiscal year ending December 31, 2021, and authorize the Company’s board of directors, or the Board, (or the Audit Committee, if authorized by the Board) to determine the compensation of the auditors in accordance with the volume and nature of their services;
2.To elect each of the following nominees to serve as directors of the Company, as follows:
(a)Re-elect Mr. Roger Garceau as a director of the Company;
(b)Re-elect Ms. Faith L. Charles as a director of the Company;
(c)Re-elect Ms. Miranda J. Toledano as a director of the Company;
(d)Ratify and approve the election of Dr. Spiros Jamas as a director of the Company;
(e)Ratify and approve the election of Mr. Ron Mayron, as a director of the Company;
3.To ratify and approve an amendment to the terms of compensation of Dr. Phillip Schwartz, our President of R&D;
4.To ratify and approve an amendment to the terms of compensation of Mr. Hillel Galitzer , our Chief Operations Officer;
5.To ratify and approve the amended terms of compensation of Ms. Dana Yaacov-Garbeli, our Israel-based Chief Financial Officer;
6.To ratify and approve the terms of compensation of Mr. Ramesh Ratan, our US-based Chief Financial Officer;
7.To ratify and approve a one-time grant of compensation to Mr. Ron Mayron, our director;
8.To ratify and approve the adoption of our amendment to our Directors and Officers Compensation Policy;
9.To approve the amended terms of compensation of the Company’s non-executive directors;
10.To ratify and approve the purchase of a professional liability insurance policy for our current and future directors and officers;
|
| 2021-06-23 |
复牌提示：
2021-06-23 09:42:45 停牌，复牌日期 2021-06-23 09:47:45
|
| 2021-01-11 |
股东大会：
将于2021-03-03召开股东大会
会议内容 ▼▲
- 1.To ratify and approve the terms of compensation of Dr. Spiros Jamas, our Chief Executive Officer and director, for a period commencing as of January 4, 2021 and onward.
2.Transact such other business as may properly come before the Meeting or any postponement or adjournment thereof
|
| 2020-05-13 |
股东大会：
将于2020-06-25召开股东大会
会议内容 ▼▲
- 1.To ratify and approve the appointment of Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Limited, or PwC, an independent registered public accounting firm, as the Company’s independent auditors for the fiscal year ending December 31, 2020, and authorize the Company’s board of directors, or the Board, (or the Audit Committee, if authorized by the Board) to determine the compensation of the auditors in accordance with the volume and nature of their services (“Proposal 1”);
2.To elect each of the following nominees to serve as directors of the Company, as follows (“Proposal 2”):
(a)Re-elect Mr. Gerald Lieberman as a Class III director of the Company, until the Company’s annual general meeting of shareholders to be held in 2023;
(b)Re-elect Mr. Gerald M. Ostrov as a Class III director of the Company, until the Company’s annual general meeting of shareholders to be held in 2023;
(c)Ratify and approve the election of Mr. Sean Ellis, as a Class III director of the Company until the Company’s annual general meeting of shareholders to be held in 2023;
(d)Ratify and approve the election of Mr. Adam Gridley as a Class II director of the Company until the Company’s annual general meeting of shareholders to be held in 2022;
3.To ratify and approve a one-time grant of compensation to Mr. Gridley, our CEO (“Proposal 3”);
4.To ratify and approve an amendment to the terms of compensation of Dr. Phillip Schwartz, our President of R&D (“Proposal 4”);
5.To ratify and approve a one-time grant of compensation to Dr. Arthur Santora, our Chief Medical Officer (“Proposal 5”);
6.To ratify and approve the amended terms of compensation of Ms. Dana Yaacov-Garbeli, our Israel-based Chief Financial Officer (“Proposal 6”);
7.To ratify and approve the purchase of a professional liability insurance policy for our current and future directors and officers (“Proposal 7”).
|
| 2020-01-14 |
股东大会：
将于2020-02-18召开股东大会
会议内容 ▼▲
- 1.To ratify and approve the terms of compensation of Mr. Jonathan Lieber, our U.S.-based Chief Financial Officer, for a period commencing as of November 21, 2019 and onward;
2.To ratify and approve the grant of 33,638 options to Mr. Sean Ellis, a non-executive director of the Company, as of November 18, 2019;
3.To approve a private placement with D.N.A Biomedical Solutions Ltd., our principal shareholder.
|
| 2019-08-29 |
股东大会：
将于2019-10-03召开股东大会
会议内容 ▼▲
- 1.To ratify and approve the terms of compensation of Mr. Adam Gridley, our Chief Executive Officer, for a period commencing as of August 5, 2019, and onward;
2.To ratify and approve the amendment of the terms of compensation of Dr. Phillip Schwartz, for a period commencing as of June 24, 2019, and onward;
3.To approve the Amendment to the Articles of Association of the Company to increase the maximum number of directors of the Company to ten directors.
|
| 2019-04-15 |
股东大会：
将于2019-05-20召开股东大会
会议内容 ▼▲
- 1.To ratify and approve the appointment of Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Limited, an independent registered public accounting firm, as the Company’s independent auditors for the fiscal year ending December 31, 2019, and authorize the Company’s board of directors, or the Board, (or the Audit Committee, if authorized by the Board) to determine the compensation of the auditors in accordance with the volume and nature of their services (Proposal 1);
2.To re-elect each of the following nominees to serve as Class II directors of the Company, each until the Company’s annual general meeting of shareholders to be held in 2022 (Proposal 2):
(a)Dr. Phillip Schwartz;
(b)Mr. Yonatan Malca;
3.To ratify and approve the election of Mr. Gerald M. Ostrov to serve as a Class III director of the Company, until the Company’s annual general meeting of shareholders to be held in 2020 (Proposal 3);
4.To approve the amended terms of compensation of the Company’s non-executive directors (Proposal 4);
5.To ratify and approve the purchase of a professional liability insurance policy for our current and future directors and officers (Proposal 5);
6.To ratify and approve the terms of compensation of our Chief Medical Officer, Dr. Arthur Santora (Proposal 6).
|
| 2018-08-23 |
股东大会：
将于2018-09-27召开股东大会
会议内容 ▼▲
- 1.Appoint Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Limited (PwC Israel), an independent registered public accounting firm, as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018, and authorize the Company's board of directors to determine the compensation of the auditors in accordance with the volume and nature of their services;
2.Re-elect each of the following nominees to serve as Class I directors of the Company, each until the Company's annual general meeting of shareholders to be held in 2021:
(a)Mr. Zeev Bronfeld;
(b)Dr. Roger Garceau
3.Elect each of the following nominees to serve as external directors of the Company, each for a period of three years commencing as of the date of the Meeting:
(a)Ms. Faith L. Charles;
(b)Ms. Miranda J. Toledano
4.Approve the Company’s Directors and Officers Compensation Policy.
|